Phase 1 Study of PTX-912 for Advanced Solid Tumors
This study is testing a new drug called PTX-912 in people with advanced or metastatic (spread to other parts of the body) solid tumors. The main goal is to see how safe PTX-912 is and how well your body tolerates different doses. Researchers will also look at how the drug moves through your body (pharmacokinetics or PK) and if your immune system reacts to it (immunogenicity). They will also check for any early signs that PTX-912 might be helping to shrink tumors. You could be eligible if you are 18 or older and have advanced solid tumors. The study will consider it a success if the drug is safe and well-tolerated, especially within the first 28 days of treatment. The current recruitment status is unclear.
- Study design
- This is a first-in-human (FIH) study, meaning it's the first time PTX-912 is being tested in people. It will involve about 26 participants.
- What's involved
- You would receive PTX-912 through an IV (intravenous) infusion every two weeks. Treatment would continue until your disease gets worse, you experience side effects that are too difficult to manage, or for a maximum of 12 months.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary safety measure (dose-limiting toxicity or DLTs) is assessed within 28 days of treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
At a glance
Conditions
NCT06190886
Where you'd take part
This study runs at 3 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
City of Hope National Medical Center
Duarte, Californiastudy coordinator listed
Recruiting
Nebraska Cancer Specialists (NCS)
Omaha, Nebraskastudy coordinator listed
Recruiting
University of Miami
Miami, Floridastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- DLTs (dose limiting toxicity)within 28 days
Frequency, severity, and duration of treatment-emergent adverse events (TEAEs) and laboratory abnormalities for all dose groups according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 5.0; except for cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) which will be graded according to American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading.